RenovoRx, Inc. (RNXT) financial statements and ratios from SEC XBRL: revenue $1.12M (TTM), net margin -994.5%, revenue growth 2511.6% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $1.12M |
| Net Margin | -994.5% |
| Revenue Growth (YoY) | 2511.6% |
| EPS Growth (YoY) | -20.0% |
| FCF Growth (YoY) | 20.1% |
| Price / Book | 5.26 |
| Price / Sales | 40.96 |
| FCF Yield | -35.0% |
| Altman Z-Score | -1.40 (distress) |
| Sector P/E (Healthcare) | 21.7 |
RNXT overview · RNXT earnings · RNXT KPIs · RNXT investor relations · RNXT ownership · RNXT peers · RNXT filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.